CBS 2019
CBSMD教育中心
English

充血性心力衰竭

科研文章

荐读文献

Angiotensin–neprilysin inhibition versus enalapril in heart failure A pragmatic approach to the use of inotropes for the management of acute and advanced heart failure: An expert panel consensus Diuretic Therapy for Patients With Heart Failure JACC State-of-the-Art Review 2018 ACC/AHA/HRS Guideline on the Evaluation and Management of Patients With Bradycardia and Cardiac Conduction Delay: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society The Future of Biomarker-Guided Therapy for Heart Failure After the Guiding Evidence-Based Therapy Using Biomarker Intensified Treatment in Heart Failure (GUIDE-IT) Study The Hospital Readmissions Reduction Program Nationwide Perspectives and Recommendations: A JACC: Heart Failure Position Paper The pyruvate-lactate axis modulates cardiac hypertrophy and heart failure A randomized controlled trial to evaluate the safety and efficacy of cardiac contractility modulation in patients with systolic heart failure: rationale, design, and baseline patient characteristics. A Fully Magnetically Levitated Left Ventricular Assist Device — Final Report Impact of Myocardial Scar on Prognostic Implication of Secondary Mitral Regurgitation in Heart Failure
|<<... 3 4 5 6 7 8 9 ...>>|

Clinical Trial2014 Sep 11;371(11):993-1004.

JOURNAL：N Engl J Med. Article Link

Angiotensin–neprilysin inhibition versus enalapril in heart failure

McMurray JJ, Packer M, PARADIGM-HF Investigators and Committees. Keywords: angiotensin receptor-neprilysin inhibitor LCZ696; enalapril; HFrEF; mortality; survival; hospitalization for heart failure

FULL TEXT PDF

>CBS CBS 2019

> CBS 2019

> CBS 2019 注册

> CBS 2019 会议日程

> CBS 2019 学术征集

> CBS 2019 热点

 CBSMD

> CBSMD 网站注册

> 教育中心

> 荐读文献

> Top 10 阅读文献

> 文献导读
CBS 2019 CBS 2019 主席团 教育中心 科研动态
Copyright ⓒ CBS MD Nanjing China. All rights reserved. 京ICP备16025898号-11
联系我们| Top